HSCT for MS: Real Results, Risks & Cost (2023)

Facing Multiple Sclerosis (MS) and searching for groundbreaking treatments? HSCT, or Hematopoietic Stem Cell Transplantation, is generating buzz for its potential to halt MS progression and offer long-lasting remission.

In this article, we cut through the complexity to give you a clear understanding of what HSCT for MS involves, its potential benefits, and the challenges you should be aware of. Let's dive into the details.

‍

HSCT for Multiple Sclerosis

HSCT, or hematopoietic stem cell transplantation, is an intense chemotherapy treatment for multiple sclerosis (MS) that aims to "reset" the immune system by wiping it out and then regrowing it using the patient's stem cells. The goal of HSCT is to stop the inflammation that contributes to MS[5]. A specific type of HSCT, known as autologous HSCT (aHSCT), uses stem cells from the patient's own body instead of donor stem cells, making it the safest form of HSCT for MS.

‍

Autologous HSCT

There is growing evidence that aHSCT may be highly effective for people with relapsing MS who meet very specific characteristics[5]. However, the success rate for people with progressive MS is lower, at about 70%. It is important to note that HSCT cannot regrow nerves or repair damaged myelin, so it may not be helpful for those with advanced progressive MS who no longer have relapses and don't show signs of inflammation on an MRI.

HSCT carries risks and side effects, including hair loss, fever, nausea, and infertility. The risk of infections in the future also increases. Some patients may develop acute graft-versus-host disease (GVHD) after allogeneic transplant, with symptoms such as rash, burning, redness of the skin, nausea, vomiting, stomach cramps, diarrhea, loss of appetite, and jaundice.

The costs of HSCT can vary widely, ranging from approximately $87,000 to $300,000. Factors influencing the cost include the type of transplant, conditioning regimen, hospitalization, and geographic location. It is important to consider the potential risks, benefits, and costs of HSCT when deciding whether it is the right treatment option for an individual with MS.

‍

Risks & Benefits

The risks and benefits of hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) patients vary depending on the individual's specific condition and the type of HSCT performed. Autologous HSCT (aHSCT) is considered the safest form of HSCT for MS, as it uses the patient's own stem cells rather than donor stem cells.

Benefits of HSCT for MS patients include:
1. Reduction in relapses and stabilization or improvement of disability for some patients, particularly those with highly active MS.
2. Halt of disease activity in some cases, preventing further progression.

Risks and side effects of HSCT for MS patients include:
1. Chemotherapy-related side effects such as hair loss, fever, nausea, and infertility.
2. Increased risk of infections in the future.
3. Potential organ damage, infection, and bleeding.
4. In the case of allogeneic transplant, the risk of acute graft-versus-host disease (GVHD) with symptoms like rash, burning, redness of the skin, nausea, vomiting, stomach cramps, diarrhea, loss of appetite, and jaundice.

It is crucial for individuals considering HSCT for MS to consult with a medical professional to weigh the potential risks and benefits of the treatment based on their specific condition and needs.

‍

Recovery Process

The recovery process after hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) can vary depending on the individual and the intensity of the treatment. Typically, people need between 3 and 6 months to recover from HSCT, but for some, it can take more than a year to fully recover. The immune system begins to recover around 2 weeks after the infusion of blood stem cells.

During the recovery period, patients may undergo rehabilitation to optimize their management and overall outcome. However, there is no established rehabilitation pathway for MS patients either before or after HSCT, and the provision of rehabilitation may vary from country to country. Rehabilitation plans should factor in the patient's initial presentation and their response to HSCT, particularly if they become systemically unwell and deconditioned during the treatment period.

Rehabilitation may include a combination of (neurological) physiotherapy, ergotherapy, psychology, relaxation therapy, and cognitive training, as well as exercise therapy in a rehabilitation room and swimming pool. At the end of the rehabilitation, the patient is given clear instructions on how to continue working towards recovery, and the healthcare provider may keep in touch with the patient about further progress in their home environment.

It is important to note that the recovery process can be different for each individual, and it is crucial to consult with a medical professional to develop a personalized recovery plan based on the patient's specific needs and condition.

‍

Common Side Effects

Common side effects of HSCT for MS patients during recovery include:

1. Fatigue and weakness
2. Temporary loss of appetite
3. Increased risk of bleeding and bruising
4. Worsening of MS symptoms for some time
5. Hair loss, which is usually temporary (lasting between one and six months) and may result in hair growing back with a slightly different color or texture

Additionally, patients may experience side effects from the chemotherapy used in HSCT, such as fever, gastrointestinal effects, and infections. It is important to note that the recovery process and side effects can vary among individuals, and patients should consult with their medical team to discuss their specific situation and potential side effects during recovery.

‍

HSCT vs Mesenchymal Stem Cell Therapy for MS

HSCT (hematopoietic stem cell transplantation) and mesenchymal stem cell therapy (MSCT) are two different stem cell therapies used to treat multiple sclerosis (MS).

HSCT involves the use of hematopoietic stem cells, which are responsible for the formation of blood cells. This treatment aims to "reset" the immune system by destroying the patient's aberrant immune cells and then reconstituting the immune system with non-autoreactive cells. HSCT has shown efficacy in treating patients with variable disease severity, with the best results observed in early-stage, rapidly progressing MS patients with active central nervous system inflammation.

On the other hand, MSCT uses mesenchymal stem cells, which are found in bone marrow and have strong anti-inflammatory and immunosuppressive properties. These cells cannot grow into new nerves or myelin cells but are thought to release chemicals that can help existing brain cells. MSCT is being explored for its potential to protect nerves from damage and encourage myelin repair. This therapy is less invasive than HSCT and does not involve chemotherapy, making it a more suitable option for patients who may be in poor condition to undergo HSCT.

In summary, HSCT and MSCT are two distinct stem cell therapies for MS with different mechanisms of action. HSCT focuses on resetting the immune system, while MSCT aims to provide anti-inflammatory and immunosuppressive effects to protect nerves and promote myelin repair. The choice between these therapies depends on the patient's specific condition and needs, and it is essential to consult with a medical professional to determine the most appropriate treatment option.

‍

Understanding Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). It occurs when the immune system mistakenly attacks the protective covering of nerve fibers, known as myelin, causing communication problems between the brain and the rest of the body. MS can lead to a wide range of physical, cognitive, and emotional symptoms, and its severity and progression can vary greatly among individuals.

‍

Explanation of MS

MS is classified into different types based on the pattern of disease progression. The most common form is relapsing-remitting MS (RRMS), characterized by periods of flare-ups or relapses followed by periods of partial or complete recovery. Another form is primary progressive MS (PPMS), where symptoms worsen steadily over time without distinct relapses. Secondary progressive MS (SPMS) is a progressive form that develops in individuals who initially had RRMS.

‍

Causes of MS

The exact cause of MS remains unknown, but research suggests that it is a combination of genetic, environmental, and immunological factors. Genetic susceptibility plays a role, as individuals with a family history of MS are at a higher risk of developing the condition. Environmental factors, such as viral infections and low levels of vitamin D, have also been linked to an increased risk of developing MS. Additionally, abnormalities in the immune system contribute to the development of MS, leading to the immune system attacking the myelin in the CNS.

‍

Symptoms of MS

MS can cause a wide variety of symptoms that may vary in severity and duration. Common symptoms include fatigue, muscle weakness and spasms, difficulty walking, coordination problems, sensory disturbances (tingling, numbness), vision problems, bladder and bowel dysfunction, cognitive impairment, and emotional changes. Symptoms can range from mild to debilitating, and can sometimes lead to significant disability.

‍

Prognosis of MS

The prognosis of MS is highly variable and unpredictable, as the progression and severity of the disease can vary greatly among individuals. Some individuals may experience mild symptoms and only occasional relapses, while others may have severe disabilities and rapid disease progression. It is challenging to predict the long-term outcome for an individual with MS, as it depends on several factors, including the type of MS, the age of onset, the individual's overall health, and the effectiveness of treatment interventions.

‍

Treatment Options for MS

While there is currently no cure for MS, several treatment options are available to manage symptoms, prevent relapses, and slow disease progression.

‍

Pharmaceutical treatments for MS

Pharmaceutical treatments for MS aim to modify the underlying immune response and reduce inflammation in the CNS. Disease-modifying therapies (DMTs) such as interferon beta, glatiramer acetate, and newer oral medications like fingolimod and dimethyl fumarate have shown effectiveness in reducing relapse rates and delaying disability progression. However, these medications may have side effects and require careful monitoring.

‍

Physical therapy for MS

Physical therapy plays a crucial role in managing the symptoms of MS and enhancing overall function and quality of life. Physical therapists design individualized exercise programs to improve strength, balance, and coordination, and address specific mobility issues. They also provide strategies for energy conservation and assistive devices to enhance independence in daily activities.

‍

Lifestyle changes to manage MS

In addition to medical interventions, certain lifestyle modifications can help individuals with MS manage their symptoms and improve overall well-being. This includes regular exercise, maintaining a balanced and nutritious diet, managing stress levels, getting adequate restorative sleep, and avoiding triggers that worsen symptoms. Engaging in activities that promote mental and emotional well-being, such as practicing mindfulness or participating in support groups, can also be beneficial for individuals with MS.

‍

Introduction to Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic Stem Cell Transplantation (HSCT), also known as bone marrow transplantation, is a procedure that involves replacing a patient's diseased or malfunctioning immune system with healthy stem cells. These stem cells are capable of generating different types of blood cells, including immune cells. HSCT has traditionally been used to treat various forms of cancer, but recent advancements have shown its potential as a treatment option for autoimmune diseases like MS.

‍

Definition of HSCT

HSCT involves the administration of high-dose chemotherapy, sometimes combined with radiation therapy, to destroy the patient's faulty immune cells. This is followed by the infusion of the patient's own or a donor's hematopoietic stem cells, which can rebuild a healthy immune system. The stem cells can be obtained from the patient's own bone marrow, peripheral blood, or umbilical cord blood, or from a compatible donor.

‍

Types of HSCT

There are different types of HSCT, depending on the source of the stem cells and the relationship between the donor and the recipient. Autologous HSCT involves using the patient's own stem cells, while allogeneic HSCT uses stem cells from a matching donor. Syngeneic HSCT is a variation of allogeneic HSCT, where the donor is an identical twin. The choice of HSCT type depends on various factors, including the patient's age, overall health, availability of a suitable donor, and the specific characteristics of the disease being treated.

‍

How HSCT Works

HSCT works by replacing the faulty immune system of an individual with a healthy one. The high-dose chemotherapy or radiation therapy used prior to the infusion of stem cells destroys the patient's abnormal immune cells, including the ones responsible for attacking the CNS in MS. The infused stem cells migrate to the bone marrow and begin producing new immune cells, effectively rebuilding the immune system. This reconstructed immune system is expected to be less prone to attacking the myelin and causing inflammation in the CNS.

‍

Using HSCT for MS Treatment

HSCT has shown promising results as a potential treatment option for individuals with aggressive, treatment-resistant MS. It is primarily considered for individuals with highly active RRMS or rapidly progressing forms like SPMS. This procedure aims to halt disease progression, improve symptoms, and potentially induce a period of long-term remission.

‍

HSCT as a treatment option for MS

HSCT is typically offered as a treatment option for individuals with MS who have failed to respond to conventional therapies or have experienced significant disability progression despite treatment. The decision to proceed with HSCT is made after a thorough evaluation by a multidisciplinary team, considering the individual's disease characteristics, overall health, and potential risks and benefits of the procedure.

‍

HSCT Procedure Steps

‍

Before the procedure

Before undergoing HSCT, individuals with MS undergo a thorough evaluation to assess their eligibility and determine the best course of action. This evaluation includes a comprehensive medical history review, neurological assessment, imaging studies, blood tests, and cardiac evaluation. A detailed discussion about the procedure and its potential risks and benefits is also carried out with the patient, ensuring that they have an understanding of the procedure and its potential outcomes.

‍

During the procedure

The HSCT procedure involves several steps, including the collection of stem cells, conditioning therapy, and stem cell infusion. If using the patient's own stem cells (autologous HSCT), stem cells are collected from the blood or bone marrow prior to the administration of high-dose chemotherapy. In allogeneic HSCT, stem cells are obtained from a suitable donor, usually a family member or unrelated donor. The collected stem cells are then cryopreserved until they are ready for infusion.

The conditioning therapy involves the administration of high-dose chemotherapy and sometimes radiation therapy. This aims to deplete the faulty immune cells, making room for the newly infused stem cells. The conditioning regimen is carefully tailored to the individual, considering factors such as disease severity and overall health. After the conditioning therapy is completed, the cryopreserved stem cells are thawed and infused into the patient's bloodstream, similar to a blood transfusion.

‍

Post-procedure care

Following HSCT, individuals require close monitoring and supportive care to manage potential complications and ensure a favorable recovery. This includes monitoring blood cell counts, managing side effects or complications related to the chemotherapy, preventing infections, and providing supportive measures such as pain management and nutrition support. Regular follow-up visits are scheduled to assess the individual's response to treatment, monitor disease activity, and provide any necessary adjustments to ongoing management.

‍

Eligibility for HSCT in MS Patients

‍

Patient criteria for HSCT

Not all individuals with MS are eligible for HSCT. The criteria for HSCT eligibility vary among different institutions, but generally, it is offered to individuals with aggressive, treatment-resistant MS who have failed to respond to standard therapies or experienced significant disability progression despite treatment. Eligibility may depend on factors such as disease activity, disease duration, age, overall health, and the presence of certain comorbidities. A multidisciplinary team of healthcare professionals specializing in MS and HSCT evaluates each patient on a case-by-case basis to determine eligibility.

‍

Factors influencing HSCT success in MS

Several factors can influence the success of HSCT in treating MS. Age at the time of HSCT, disease duration, level of disability, and the presence of specific disease characteristics, such as the presence of active inflammation on imaging studies, are some of the factors that may impact outcomes. Additionally, careful patient selection, comprehensive patient monitoring, and appropriate post-procedure care contribute to the success of HSCT and minimize the risks associated with the procedure.

‍

Cost and Coverage of HSCT for MS

‍

Estimated cost of HSCT for MS

The cost of HSCT for MS can vary significantly depending on factors such as the country or institution where the treatment is performed, the type of HSCT, the specific procedures involved, and the complexity of the patient's case. Estimates suggest that the cost of HSCT for MS can range from tens of thousands of dollars to several hundred thousand dollars. It is essential for individuals considering HSCT as a treatment option to discuss the specific costs involved with their healthcare providers and insurance companies.

‍

Insurance coverage for HSCT in MS

Insurance coverage for HSCT in MS varies widely depending on the insurance provider, the specific policy, and the country's healthcare system. While some insurance policies may cover the costs of HSCT for MS, others may require pre-authorization or consider HSCT experimental and not covered. It is crucial for individuals considering HSCT to closely review their insurance policy, consult with their insurance provider, and explore other potential sources of financial assistance or support, such as patient assistance programs and foundations.

‍

Availability of HSCT for MS worldwide

The availability of HSCT for MS varies worldwide. HSCT for MS is currently performed in specialized medical centers and research institutions, with varying degrees of accessibility. The procedure may be more readily available in countries with advanced healthcare systems and where HSCT is an established treatment option for other diseases. However, the demand for HSCT for MS has been growing, leading to an increase in the number of medical centers offering this treatment. Individuals interested in HSCT should consult with healthcare professionals to explore the availability of HSCT in their region and determine the best course of action.

‍

Recovery Process post HSCT

‍

Short-term recovery

The short-term recovery following HSCT varies among individuals but generally involves a period of hospitalization and close monitoring. The immediate few weeks after HSCT are characterized by a gradual engraftment of the infused stem cells and the recovery of blood cell counts. During this time, individuals may experience side effects related to the high-dose chemotherapy and conditioning therapy, including fatigue, loss of appetite, nausea, hair loss, and increased susceptibility to infections. Supportive care and symptom management are crucial during this period to promote recovery and minimize complications.

‍

Long-term recovery

The long-term recovery following HSCT is a dynamic process that extends beyond the immediate post-procedure period. Individuals require ongoing follow-up and monitoring by their healthcare team to assess disease activity, monitor treatment response, and manage any potential complications or side effects that may arise. Achieving the desired treatment outcomes and maintaining disease stability often require a combination of ongoing medical management, rehabilitation therapies, and lifestyle modifications. Long-term recovery may involve adjustments to medication regimens, physical and occupational therapy, and strategies to address potential disease relapses or symptom fluctuations.

‍

Impact on quality of life

HSCT has the potential to significantly improve the quality of life for individuals with MS, particularly those with aggressive, treatment-resistant disease. Studies have shown that HSCT can lead to improvements in physical function, cognitive function, and overall well-being. The reduction in disease activity and disability progression can enhance independence, daily functioning, and participation in activities. However, it is important to highlight that the impact on quality of life may vary among individuals, and it is crucial to manage expectations and address any ongoing symptoms or limitations through appropriate medical and supportive interventions.

‍

Clinical Trials and Research on HSCT for MS

‍

Current clinical trials

Ongoing clinical trials continue to evaluate the safety and efficacy of HSCT as a treatment option for MS. These trials aim to further refine patient selection criteria, optimize conditioning regimens, assess long-term outcomes, and explore potential variations in treatment protocols. Participating in clinical trials allows individuals to contribute to the advancement of HSCT for MS and potentially access novel treatment options. It is important for individuals interested in HSCT to explore available clinical trial opportunities and discuss potential enrollment with their healthcare providers.

‍

Results of past research

Past research on HSCT for MS has shown promising results. Several small-scale studies have reported significant reductions in disease activity, relapse rates, and disability progression following HSCT. Long-term follow-up studies have demonstrated sustained benefits and improved quality of life over years of post-HSCT follow-up. However, it is essential to interpret these results with caution, as larger studies with longer follow-up periods are needed to establish the long-term safety and efficacy of HSCT for MS.

‍

Possible future developments

The field of HSCT for MS is continually evolving, and ongoing research may contribute to further advancements in this treatment approach. Future developments may focus on refining patient selection criteria, optimizing conditioning regimens, exploring the potential benefits of HSCT in different types of MS, and investigating the use of novel stem cell sources or manipulation techniques. Additionally, research may explore combinations of HSCT with other therapeutic approaches, such as immune-modulating agents or different rehabilitation strategies, to maximize treatment outcomes.